2026 Q2 -tulosraportti
38 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,09%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 785 | - | - | ||
| 135 | - | - | ||
| 9 150 | - | - | ||
| 200 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sitten · MuokattuHere are the AI expectations for the staff meeting on Tuesday (I have the paid version (pro)) : According to an employee invitation seen by Bloomberg, Novo Nordisk has summoned employees to a global town hall meeting on Tuesday, September 15. The wording in the invitation is that management will share an “exciting update about our company’s next chapter”. Novo has confirmed that the internal event is taking place. The interesting thing is that the meeting is only six days before Capital Markets Day on September 21. Novo itself describes CMD as a day where top management will review strategy, R&D pipeline, business, and performance. What do I think it's about? There is no public confirmation of the content itself yet, so I would be cautious about rumors of, for example, new layoffs. But the phrasing “exciting update” and “next chapter” makes me lean more towards a major strategic presentation than another ordinary cost-saving exercise. My preliminary probability estimate is approximately: Possibility My estimate 🟢 New strategic direction / organization / growth plan 45 % 🟢 Major pipeline or product strategy 25 % 🟡 Management/organizational changes 15 % 🔴 New major layoff/cost-saving plan 10 % 🟣 Something completely different, e.g., major transaction 5 % I especially think further massive layoffs seem less obvious. Novo already announced a transformation last year with approximately 9,000 positions eliminated and DKK 8 billion in annual savings. At Q2 2026, management also stated that they were ahead of schedule in realizing these savings. There are indeed employee rumors about another round of layoffs in September, but these are just rumors and not documentation. What I find most exciting I believe there might be a direct connection between: September 15 → employees are presented with “Novo's next chapter” September 21 → investors receive the financial and strategic explanation at Capital Markets Day. This actually fits very well with what we discussed regarding CMD: Novo needs to convince the market that 2025–26 was a transition period, and that Wegovy/oral Wegovy, CagriSema, amycretin/zenaiglutide and the rest of the pipeline can create a new growth period. I will therefore consider Tuesday's meeting as potentially price-sensitive. The wording in the invitation is unusually positive. This does not necessarily mean that a major stock exchange announcement will come on Tuesday, but I think the probability of getting a first hint of what Novo will present at CMD is quite high. And since you bought Novo around 276 kr., I actually think that the period September 15–21 could be one of the more interesting weeks for your Novo investment this year. I can keep an eye on new information and rumors leading up to Tuesday and let you know if anything credible emerges about what “next chapter” specifically means.
·3 t sittenNovo Nordisk has obtained Chinese approval for the obesity drug Wegovy as a treatment for non-alcoholic fatty liver, MASH. This is stated in a press release from Novo Nordisk. It is China's national health authorities that have given the green light for Wegovy to now also be used as a treatment for MASH in China, Novo Nordisk has had its price target raised by the major bank HSBC to 320 kroner from 300 kroner. The recommendation remains hold. This is according to Bloomberg News.
·5 t sittenBodø/Glimt announces Saturday morning that they have entered into a collaboration with Novo Nordisk!
·4 t sitten · MuokattuOne must say that weak has dumped shares since 314 a couple of weeks ago. To think that they have dumped many cheap Novo shares. They have only themselves to blame. Now Novo has fortunately found yet another solid bottom at 275. One wonders where the real bottom is. It's all certainly due to thin trading, shorts, algorithms, Trump ect...... ....according to the oracle. Novo is of course not to blame for the fall. Everyone else has been to blame for two years.
We had a long positive period leading up to Q2 where the price rose from approx. 270 (before that from 228) to 338 around August 1st - if you don't remember it, I'm sure others do. But after the Q2 upward adjustment, sentiment changed and everything suddenly became negative??, yes after USA dumped the price in 30 sec. at the upward adjustment. (that was 1 month and 12 days ago)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
38 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,09%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten · MuokattuHere are the AI expectations for the staff meeting on Tuesday (I have the paid version (pro)) : According to an employee invitation seen by Bloomberg, Novo Nordisk has summoned employees to a global town hall meeting on Tuesday, September 15. The wording in the invitation is that management will share an “exciting update about our company’s next chapter”. Novo has confirmed that the internal event is taking place. The interesting thing is that the meeting is only six days before Capital Markets Day on September 21. Novo itself describes CMD as a day where top management will review strategy, R&D pipeline, business, and performance. What do I think it's about? There is no public confirmation of the content itself yet, so I would be cautious about rumors of, for example, new layoffs. But the phrasing “exciting update” and “next chapter” makes me lean more towards a major strategic presentation than another ordinary cost-saving exercise. My preliminary probability estimate is approximately: Possibility My estimate 🟢 New strategic direction / organization / growth plan 45 % 🟢 Major pipeline or product strategy 25 % 🟡 Management/organizational changes 15 % 🔴 New major layoff/cost-saving plan 10 % 🟣 Something completely different, e.g., major transaction 5 % I especially think further massive layoffs seem less obvious. Novo already announced a transformation last year with approximately 9,000 positions eliminated and DKK 8 billion in annual savings. At Q2 2026, management also stated that they were ahead of schedule in realizing these savings. There are indeed employee rumors about another round of layoffs in September, but these are just rumors and not documentation. What I find most exciting I believe there might be a direct connection between: September 15 → employees are presented with “Novo's next chapter” September 21 → investors receive the financial and strategic explanation at Capital Markets Day. This actually fits very well with what we discussed regarding CMD: Novo needs to convince the market that 2025–26 was a transition period, and that Wegovy/oral Wegovy, CagriSema, amycretin/zenaiglutide and the rest of the pipeline can create a new growth period. I will therefore consider Tuesday's meeting as potentially price-sensitive. The wording in the invitation is unusually positive. This does not necessarily mean that a major stock exchange announcement will come on Tuesday, but I think the probability of getting a first hint of what Novo will present at CMD is quite high. And since you bought Novo around 276 kr., I actually think that the period September 15–21 could be one of the more interesting weeks for your Novo investment this year. I can keep an eye on new information and rumors leading up to Tuesday and let you know if anything credible emerges about what “next chapter” specifically means.
- ·3 t sittenNovo Nordisk has obtained Chinese approval for the obesity drug Wegovy as a treatment for non-alcoholic fatty liver, MASH. This is stated in a press release from Novo Nordisk. It is China's national health authorities that have given the green light for Wegovy to now also be used as a treatment for MASH in China, Novo Nordisk has had its price target raised by the major bank HSBC to 320 kroner from 300 kroner. The recommendation remains hold. This is according to Bloomberg News.
- ·5 t sittenBodø/Glimt announces Saturday morning that they have entered into a collaboration with Novo Nordisk!
- ·4 t sitten · MuokattuOne must say that weak has dumped shares since 314 a couple of weeks ago. To think that they have dumped many cheap Novo shares. They have only themselves to blame. Now Novo has fortunately found yet another solid bottom at 275. One wonders where the real bottom is. It's all certainly due to thin trading, shorts, algorithms, Trump ect...... ....according to the oracle. Novo is of course not to blame for the fall. Everyone else has been to blame for two years.We had a long positive period leading up to Q2 where the price rose from approx. 270 (before that from 228) to 338 around August 1st - if you don't remember it, I'm sure others do. But after the Q2 upward adjustment, sentiment changed and everything suddenly became negative??, yes after USA dumped the price in 30 sec. at the upward adjustment. (that was 1 month and 12 days ago)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 785 | - | - | ||
| 135 | - | - | ||
| 9 150 | - | - | ||
| 200 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
38 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
4,09%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten · MuokattuHere are the AI expectations for the staff meeting on Tuesday (I have the paid version (pro)) : According to an employee invitation seen by Bloomberg, Novo Nordisk has summoned employees to a global town hall meeting on Tuesday, September 15. The wording in the invitation is that management will share an “exciting update about our company’s next chapter”. Novo has confirmed that the internal event is taking place. The interesting thing is that the meeting is only six days before Capital Markets Day on September 21. Novo itself describes CMD as a day where top management will review strategy, R&D pipeline, business, and performance. What do I think it's about? There is no public confirmation of the content itself yet, so I would be cautious about rumors of, for example, new layoffs. But the phrasing “exciting update” and “next chapter” makes me lean more towards a major strategic presentation than another ordinary cost-saving exercise. My preliminary probability estimate is approximately: Possibility My estimate 🟢 New strategic direction / organization / growth plan 45 % 🟢 Major pipeline or product strategy 25 % 🟡 Management/organizational changes 15 % 🔴 New major layoff/cost-saving plan 10 % 🟣 Something completely different, e.g., major transaction 5 % I especially think further massive layoffs seem less obvious. Novo already announced a transformation last year with approximately 9,000 positions eliminated and DKK 8 billion in annual savings. At Q2 2026, management also stated that they were ahead of schedule in realizing these savings. There are indeed employee rumors about another round of layoffs in September, but these are just rumors and not documentation. What I find most exciting I believe there might be a direct connection between: September 15 → employees are presented with “Novo's next chapter” September 21 → investors receive the financial and strategic explanation at Capital Markets Day. This actually fits very well with what we discussed regarding CMD: Novo needs to convince the market that 2025–26 was a transition period, and that Wegovy/oral Wegovy, CagriSema, amycretin/zenaiglutide and the rest of the pipeline can create a new growth period. I will therefore consider Tuesday's meeting as potentially price-sensitive. The wording in the invitation is unusually positive. This does not necessarily mean that a major stock exchange announcement will come on Tuesday, but I think the probability of getting a first hint of what Novo will present at CMD is quite high. And since you bought Novo around 276 kr., I actually think that the period September 15–21 could be one of the more interesting weeks for your Novo investment this year. I can keep an eye on new information and rumors leading up to Tuesday and let you know if anything credible emerges about what “next chapter” specifically means.
- ·3 t sittenNovo Nordisk has obtained Chinese approval for the obesity drug Wegovy as a treatment for non-alcoholic fatty liver, MASH. This is stated in a press release from Novo Nordisk. It is China's national health authorities that have given the green light for Wegovy to now also be used as a treatment for MASH in China, Novo Nordisk has had its price target raised by the major bank HSBC to 320 kroner from 300 kroner. The recommendation remains hold. This is according to Bloomberg News.
- ·5 t sittenBodø/Glimt announces Saturday morning that they have entered into a collaboration with Novo Nordisk!
- ·4 t sitten · MuokattuOne must say that weak has dumped shares since 314 a couple of weeks ago. To think that they have dumped many cheap Novo shares. They have only themselves to blame. Now Novo has fortunately found yet another solid bottom at 275. One wonders where the real bottom is. It's all certainly due to thin trading, shorts, algorithms, Trump ect...... ....according to the oracle. Novo is of course not to blame for the fall. Everyone else has been to blame for two years.We had a long positive period leading up to Q2 where the price rose from approx. 270 (before that from 228) to 338 around August 1st - if you don't remember it, I'm sure others do. But after the Q2 upward adjustment, sentiment changed and everything suddenly became negative??, yes after USA dumped the price in 30 sec. at the upward adjustment. (that was 1 month and 12 days ago)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 785 | - | - | ||
| 135 | - | - | ||
| 9 150 | - | - | ||
| 200 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt